nct_id: NCT04008797
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2019-07-05'
study_start_date: '2019-07-11'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Lenvatinib'
  - drug_name: 'Drug: Doxorubicin'
  - drug_name: 'Drug: E7386'
  - drug_name: 'Drug: Paclitaxel'
long_title: An Open-label Study of E7386 in Combination With Other Anticancer Drug(s)
  in Subjects With Solid Tumors
last_updated: '2025-11-12'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: Eisai Inc.
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 301
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '1. HCC part only:'
- 'Participants with confirmed diagnosis of unresectable HCC with any of the following
  criteria:'
- 1. Histologically or cytologically confirmed diagnosis of HCC, excluding fibrolamellar,
  sarcomatoid or mixed cholangio-HCC tumors
- 2. Clinically confirmed diagnosis of HCC according to American Association for the
  Study of Liver Diseases (AASLD) criteria, including cirrhosis of any etiology and/or
  chronic hepatitis B or C infection
- 'ST part only (except for HCC):'
- Participants with histologically or cytologically confirmed diagnosis of solid tumor
  for which no alternative standard therapy or no effective therapy exists
- 2. Life expectancy of \>=12 weeks
- 3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
- 4. All AEs due to previous anti-cancer therapy have either returned to Grade 0 to
  1 except for alopecia or up to Grade 2 peripheral neuropathy (renal/bone marrow/liver
  function should meet the inclusion criteria)
- '5. Adequate washout period before study drug administration:'
- '1. Chemotherapy and radiotherapy: 3 weeks or 5 times the half-life, whichever is
  shorter'
- '2. Any antitumor therapy with antibody: 4 weeks or more'
- '3. Any investigational drug or device: 4 weeks or more'
- '4. Blood/platelet transfusion or granulocyte colony-stimulating factor (G-CSF):
  2 weeks or more Note: Participants must have recovered from all radiation-related
  toxicities, not require corticosteroids, and not had radiation pneumonitis'
- 6. Adequate controlled blood pressure (BP), renal function, bone marrow function,
  liver function, and serum mineral level
- 7. At least one measurable lesion based on mRECIST (for HCC Subparts in Dose Escalation
  Part) or on RECIST 1.1 (for Other ST Subparts in Dose Escalation Part and all subparts
  in Expansion and Dose Optimization Parts) meeting following criteria
- '* At least 1 lesion of \>=1.0 centimeter (cm) in the longest diameter for a non-lymph
  node or \>=1.5 cm in the short-axis diameter for a lymph node that is serially measurable
  according to RECIST 1.1 using computerized tomography (CT)/magnetic resonance imaging
  (MRI)'
- '* Lesions that have had external beam radiotherapy or loco-regional therapies such
  as radiofrequency ablation, or transarterial chemoembolisation (TACE)/ transarterial
  embolization (TAE) must show evidence of progressive disease based on RECIST 1.1
  to be deemed a target lesion'
- '8. For HCC participants only: Child-Pugh score A. Note: If Child-Pugh score 7 or
  more was observed during Screening or Baseline, the participant is ineligible and
  re-assessment of the Child-Pugh score is not permitted'
- '9. For HCC participants only: Participants categorized to stage B (not amenable
  to locoregional therapy or refractory to locoregional therapy, and not amenable
  to a curative treatment), or stage C based on Barcelona Clinic Liver Cancer (BCLC)
  staging system'
- '10. For HCC Subpart in Expansion Part only: prior systemic therapy for locally
  advanced or metastatic disease is as defined below'
- a. Participants who have received only one prior line of immuno oncology (IO) based
  regimen and have progressed on or after prior treatment with IO based regimen, or
  IO ineligible participants who have received no prior systemic therapy. Participants
  who previously received lenvatinib treatment are ineligible
- '11. For CRC Subpart in Expansion Part only: participants must have received at
  least 2 prior regimens (not exceeding 4 prior regimens) or could not tolerate standard
  treatment and must have received the following prior therapies in the metastatic
  setting if approved and locally available (progressed on at least 1 prior regimen
  in the metastatic setting or could not tolerate standard treatment):'
- 'Note: Adjuvant chemotherapy counts as prior systemic treatment if there is documented
  disease progression within 6 months of treatment completion Note: If a participant
  is determined to be intolerant to prior standard treatment, the participant must
  have received at least of 2 cycles of that therapy Note: Participants who have received
  oral tyrosine kinase inhibitor (example, regorafenib) are ineligible'
- '1. Fluoropyrimidine, irinotecan and oxaliplatin with or without an anti-Vascular
  endothelial growth factor (VEGF) monoclonal antibody (mAb) (example, bevacizumab)
  Note: Capecitabine is acceptable as equivalent to fluoropyrimidine in prior treatment
  Note: Participants who have previously received fluoropyrimidine, oxaliplatin, and
  irinotecan as part of the same and only chemotherapy regimen, example, FOLFOXIRI
  or FOLFIRINOX, may be eligible after discussion with the Sponsor'
- '2. Chemotherapy with anti- epidermal growth factor receptor (EGFR) mAb (cetuximab
  or panitumumab) for participants with rat sarcoma virus (RAS) (Kirsten rat sarcoma
  viral oncogene homolog \[KRAS)/ NRAS\]) wild type (WT) CRC Note: RAS (KRAS/NRAS)
  WT participants with right or left CRC lesions who may have not been treated with
  anti-EGFR mAb based on local guidelines are eligible'
- "3. BRAF inhibitor (in combination with cetuximab \xB1 binimetinib) for BRAF V600E\
  \ mutated tumors"
- 4. Immune checkpoint inhibitor for participants with microsatellite instability-high
  (MSI-H) CRC
- '12. For EC Subpart in Expansion Part only: Participants must have EC that has progressed
  after prior platinum-based chemotherapy and an anti-programmed cell death (ligand)
  1 (PD-\[L\])1)-directed therapy for EC (participants ineligible for IO therapy who
  have progressed after prior platinum-based chemotherapy are eligible). Up to 3 prior
  systemic therapies, of which up to 2 for metastatic or locally advanced disease,
  are permitted Note: There is no restriction regarding prior hormonal therapies For
  Dose Optimization Part only: Participants must have EC that has progressed after
  prior platinum-based chemotherapy and an anti-PD-(L)1-directed therapy for EC. Up
  to 3 lines of prior therapy, regardless of setting, are allowed. Participants must
  be eligible for treatment with either single-agent paclitaxel or single-agent doxorubicin
  as determined by the investigator, with consideration of previous therapies received
  for EC. Note: Prior hormonal therapy and radiation are allowed and do not count
  as prior lines of therapy.'
- 'Exclude - Exclusion Criteria:'
- 'Exclude - 1. Any of cardiac conditions as follows:'
- Exclude - * Heart failure New York Heart Association (NYHA) Class II or above
- Exclude - * Prolongation of QT interval with Fridericias correction (QTcF) to greater
  than (\>) 480 millisecond (msec)
- Exclude - * Left ventricular ejection fraction (LVEF) less than (\<) 50 percent
  (%)
- 'Exclude - 2. Major surgery within 21 days or minor surgery (that is, simple excision)
  within 7 days prior to starting study drug. Participant must have recovered from
  the surgery related toxicities to less than Grade 2 Note: Adequate wound healing
  after major surgery must be assessed clinically, independent of time elapsed for
  eligibility'
- 'Exclude - 3. Known to be human immunodeficiency virus (HIV) positive Note: the
  sponsor has evaluated whether to include participant with HIV. Given that this is
  the first combination study of E7386 with lenvatinib and that the main mechanism
  of action of E7386 is immunomodulation of the tumor microenvironment along with
  the fact that several anti-retroviral therapies have drug-drug interaction with
  cytochrome P450 3A (CYP3A) substrates, the sponsor has decided not to include these
  participants at the current time. However, further considerations will be made moving
  forward based on new emerging data Note: HIV testing is required at screening only
  when mandated by local health authority'
- Exclude - 4. Participants with proteinuria on urine dipstick testing will undergo
  24-hour urine collection for quantitative assessment of proteinuria. Participants
  with urine protein \>=1 gram per 24 hour will be ineligible
- Exclude - 5. Active infection requiring systemic treatment (Except for Hepatitis
  B and/or C \[HBV/HCV\] infection in HCC participants)
- 'Exclude - In case of HBsAg (+) participants in HCC participants:'
- Exclude - * Antiviral therapy for HBV is not ongoing
- Exclude - * HBV viral load is 2000 international unit per milliliter (IU/mL) or
  more at the Screening Period although antiviral therapy for HBV is ongoing
- Exclude - * Has dual active HBV infection (HBsAg (+) and/or detectable HBV deoxyribonucleic
  acid \[DNA\]) and HCV infection (anti-HCV Ab (+) and detectable HCV ribonucleic
  acid \[RNA\]) at study entry
- Exclude - 6. Diagnosed with meningeal carcinomatosis
- Exclude - 7. Participants with central nervous system metastases are only eligible
  if they have been previously treated and are radiologically stable, (that is, without
  evidence of progression for at least 4 weeks prior to first dose of study treatment
  by repeat imaging), clinically stable, and without requirement of steroid treatment
  for at least 14 days prior to first dose of study treatment
- Exclude - 8. Pulmonary lymphangitic involvement that results in pulmonary dysfunction
  requiring active treatment, including the use of oxygen
- 'Exclude - 9. Any of bone disease/conditions as follows:'
- Exclude - * T-score of \< minus (-) 3.0 at the left or right total hip, left or
  right femoral neck or lumbar spine (L1-L4) as determined by dual energy x-ray absorptiometry
  (DXA) scan. Participants with T-score \<-2.5 to -3.0 can only be included if treatment
  with a bisphosphonate (example, zoledronic acid) or denosumab has been started at
  least 14 days and no more than 6 months prior to the first dose of study drug
- Exclude - * Metabolic bone disease, such as hyperparathyroidism, Paget's disease
  or osteomalacia
- Exclude - * Symptomatic hypercalcemia requiring bisphosphonate therapy
- Exclude - * History of any fracture within 6 months prior to starting study drug
- Exclude - * Bone metastasis requiring orthopedic intervention
- Exclude - * Bone metastasis not being treated by bisphosphonate or denosumab. Participants
  may be included if treatment with bisphosphonate or denosumab has been started at
  least 14 days prior to the first dose of study drug. Participants with previous
  solitary bone lesions controlled with radiotherapy are eligible
- Exclude - * History of symptomatic vertebral fragility fracture or any fragility
  fracture of the hip, pelvis, wrist or other location (defined as any fracture without
  a history of trauma or because of a fall from standing height or less)
- Exclude - * Moderate (25% to 40% decrease in the height of any vertebrae) or severe
  (\>40% decrease in the height of any vertebrae) morphometric vertebral fracture
  at baseline
- Exclude - 10. History of malignancy (except for original disease, or definitively
  treated melanoma in-situ, basal or squamous cell carcinoma of the skin, carcinoma
  in-situ \[example, bladder or cervix\]) within the past 24 months prior to the first
  dose of study drug
- 'Exclude - 11. For HCC Subpart in Dose Escalation Part only: Participants who experienced
  discontinuation of lenvatinib, 2 or more dose reductions of lenvatinib required
  from initial dose level of this study due to its toxicity, or participants who experienced
  single dose reduction or consecutive \>=8 days dose interruption of lenvatinib within
  60 days from the first dose, due to its toxicity. HCC Subpart in Expansion Part
  only: Participants who previously received lenvatinib treatment are ineligible.'
- 'Exclude - EC Subpart in Expansion Part only: Participants previously treated with
  lenvatinib who experienced discontinuation of lenvatinib due to toxicity, or dose
  reduction to less than 10 mg of lenvatinib due to toxicity within 60 days from the
  first dose.'
- 'Exclude - EC Dose Optimization Part only: Participants who previously received
  lenvatinib treatment are ineligible.'
- Exclude - 12. Bleeding or thrombotic disorders or use of anticoagulants requiring
  therapeutic International Normalized Ratio (INR) monitoring for HCC participants
  only (example, warfarin or similar agents). Treatment with low molecular weight
  heparin and factor X inhibitors is permitted. Treatment with antiplatelet agents
  is prohibited for HCC participants in Dose Escalation Part only
- Exclude - 13. Gastrointestinal bleeding event or active hemoptysis (bright red blood
  of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug
- 'Exclude - 14. For HCC participants only: History of hepatic encephalopathy within
  6 months prior to starting study drug'
- 'Exclude - 15. For EC Subpart in Expansion and Dose Optimization Parts only: carcinosarcoma
  (malignant mixed Mullerian tumor), endometrial leiomyosarcoma, and endometrial stromal
  sarcomas'
- Exclude - 16. Has preexisting \>=Grade 3 gastrointestinal or non-gastrointestinal
  fistula
- Exclude - 17. Evidence of current Coronavirus disease 2019 (COVID-19) infection
  or ongoing unrecovered active sequelae of COVID-19 infection
- Exclude - 18. Males who have not had a successful vasectomy (confirmed azoospermia)
  if their female partners meet the exclusion criteria above (that is, the female
  partners are of childbearing potential and are not willing to use a highly effective
  contraceptive method throughout the study period and after study drug discontinuation).
  No sperm donation is allowed during the study period and after study drug discontinuation
- Exclude - 19. Has a known psychiatric or substance abuse disorder that would interfere
  with the participant ability to cooperate with the requirements of the study
- Exclude - 20. Evidence of clinically significant disease (example, cardiac, respiratory,
  gastrointestinal, renal disease) that in the opinion of the investigator could affect
  the participant safety or interfere with the study assessments
- Exclude - 21. Scheduled for major surgery during the study
short_title: A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants
  With Solid Tumor
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Eisai Inc.
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The primary objective of this study is to assess the safety and tolerability
  and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with
  other anticancer drug(s), and to determine the optimal dose of E7386 in combination
  with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: 'Dose Escalation Part: HCC: E7386 QD Subpart + Lenvatinib'
      arm_internal_id: 0
      arm_description: Participants with hepatocellular carcinoma (HCC) will receive
        E7386, once daily (QD) for 5 or 6 consecutive days followed by a period of
        time without treatment in Cycle 0 (6 or 7 days). Participants with HCC will
        receive E7386, QD in combination with lenvatinib 8 milligram (mg) (participants
        with body weight of less than \[\<\] 60 kilograms \[kg\]) or 12 mg (participants
        with body weight \>=60 kg), capsules, orally, QD in 28-day treatment cycles
        until PD, development of unacceptable toxicity, participant request to discontinue,
        withdrawal of consent, or termination of the study program.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: E7386'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Lenvatinib'
        level_internal_id: 1
        level_suspended: N
    - arm_code: 'Dose Escalation Part: HCC: E7386 BID Subpart + Lenvatinib'
      arm_internal_id: 1
      arm_description: Participants with HCC will receive E7386, twice daily (BID)
        for 5 or 6 consecutive days in Cycle 0 (6 or 7 days). Participants with HCC
        will receive E7386, BID in combination with lenvatinib 8 mg (participants
        with body weight of \< 60 kg) or 12 mg (participants with body weight \>=60
        kg) capsules, orally, QD in 28-day treatment cycles until PD, development
        of unacceptable toxicity, participant request to discontinue, withdrawal of
        consent, or termination of the study program.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: E7386'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Lenvatinib'
        level_internal_id: 1
        level_suspended: N
    - arm_code: 'Dose Escalation Part: Other ST: E7386 QD Subpart + Lenvatinib'
      arm_internal_id: 2
      arm_description: Participants with solid tumor (ST) (except for HCC) will receive
        E7386, QD for 5 or 6 consecutive days followed by a period of time without
        treatment in Cycle 0 (6 or 7 days). Participants with ST (except for HCC)
        will receive E7386, QD in combination with lenvatinib 20 mg, capsules, orally,
        QD in 28-day treatment cycles until PD, development of unacceptable toxicity,
        participant request to discontinue, withdrawal of consent, or termination
        of the study program.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: E7386'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Lenvatinib'
        level_internal_id: 1
        level_suspended: N
    - arm_code: 'Dose Escalation Part: Other ST: E7386 BID Subpart + Lenvatinib'
      arm_internal_id: 3
      arm_description: Participants with ST (except for HCC) will receive E7386, BID
        for 5 or 6 consecutive days in Cycle 0 (6 or 7 days). Participants with ST
        (except for HCC) will receive E7386, BID in combination with lenvatinib 20
        mg, capsules, orally, QD in 28-day treatment cycles until PD, development
        of unacceptable toxicity, participant request to discontinue, withdrawal of
        consent, or termination of the study program.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: E7386'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Lenvatinib'
        level_internal_id: 1
        level_suspended: N
    - arm_code: 'Dose Expansion Part: HCC Subpart: Lenvatinib Only'
      arm_internal_id: 4
      arm_description: Participants with HCC will receive lenvatinib 8 mg (participants
        with body weight of \<60 kg) or 12 mg (participants with body weight \>=60
        kg), capsules, orally, QD in 28-day treatment cycles until PD, development
        of unacceptable toxicity, participant request to discontinue, withdrawal of
        consent, or termination of the study program
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Lenvatinib'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Dose Expansion Part: HCC Subpart: E7386 + Lenvatinib'
      arm_internal_id: 5
      arm_description: Participants with HCC will receive lenvatinib 8 mg (participants
        with body weight of \<60 kg) or 12 mg (participants with body weight \>=60
        kg), capsule, orally QD in combination with E7386 y, BID in 28-day treatment
        cycles until PD, development of unacceptable toxicity, participant request
        to discontinue, withdrawal of consent, or termination of the study program.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: E7386'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Lenvatinib'
        level_internal_id: 1
        level_suspended: N
    - arm_code: 'Dose Expansion Part: CRC Subpart: E7386 + Lenvatinib'
      arm_internal_id: 6
      arm_description: Participants with colorectal cancer (CRC) will receive E7386,
        BID in combination with lenvatinib 20 mg, capsules, orally, QD in 28-day treatment
        cycles until PD, development of unacceptable toxicity, participant request
        to discontinue, withdrawal of consent, or termination of the study program.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: E7386'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Lenvatinib'
        level_internal_id: 1
        level_suspended: N
    - arm_code: 'Dose Expansion Part: EC Subpart: E7386 + Lenvatinib'
      arm_internal_id: 7
      arm_description: Participants with endometrial cancer (EC) will receive E7386,
        BID in combination with lenvatinib 14 mg, capsules, orally, QD in 28-day treatment
        cycles until PD, development of unacceptable toxicity, participant request
        to discontinue, withdrawal of consent, or termination of the study program.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: E7386'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Lenvatinib'
        level_internal_id: 1
        level_suspended: N
    - arm_code: 'Dose Optimization Part: EC Participants'
      arm_internal_id: 8
      arm_description: Participants with EC will be randomized to receive 2 different
        doses of E7386 in combination with lenvatinib capsule or lenvatinib capsule
        monotherapy in 28-days cycles, or treatment of physician's choice (TPC; doxorubicin
        in 21-day cycles or paclitaxel in 28-day cycles \[3 weeks on/1 week off\]),
        until PD, development of unacceptable toxicity, participant request to discontinue,
        withdrawal of consent, or termination of the study program.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: E7386'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Lenvatinib'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Doxorubicin'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Paclitaxel'
        level_internal_id: 3
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        disease_status:
        - Unresectable
        - Refractory
        - Locally Advanced
        - Metastatic
        oncotree_primary_diagnosis: _SOLID_
